Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

aTyr Pharma, Inc. (LIFE)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
2.8400+0.0400 (+1.43%)
At close: 04:00PM EDT
2.9000 +0.06 (+2.11%)
After hours: 05:21PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Inverted Hammer

Inverted Hammer

Previous Close2.8000
Open2.8070
Bid2.8100 x 800
Ask2.9100 x 900
Day's Range2.8000 - 2.8990
52 Week Range2.6800 - 13.1000
Volume67,660
Avg. Volume119,020
Market Cap79.68M
Beta (5Y Monthly)1.55
PE Ratio (TTM)N/A
EPS (TTM)-1.7220
Earnings DateAug 08, 2022 - Aug 12, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est17.71
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for LIFE

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • aTyr Pharma, Inc.
    Analyst Report: Biogen Inc.Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
    Rating
    Fair Value
    Economic Moat
    3 days agoMorningstar
View more
  • GlobeNewswire

    aTyr Pharma Presents Clinical Data for Efzofitimod (ATYR1923) at the American Thoracic Society 2022 International Conference

    Results from Phase 1b/2a study of efzofitimod in pulmonary sarcoidosis patients demonstrate dose-dependent improvements in key physiologic and quality of life measures in context of a steroid taper. Efzofitimod treatment reduces pro-inflammatory serum biomarkers in pulmonary sarcoidosis patients. Global pivotal Phase 3 EFZO-FIT™ study on track to initiate in the third quarter of 2022. SAN DIEGO, May 17, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged

  • GlobeNewswire

    aTyr Pharma Announces Phase 3 Study of Efzofitimod (ATYR1923) in Pulmonary Sarcoidosis

    Global pivotal EFZO-FIT™ study expected to begin in the third quarter of 2022 Primary endpoint will evaluate steroid sparing effect of efzofitimod compared to placebo SAN DIEGO, May 16, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines from its proprietary tRNA synthetase platform, today announced a Phase 3 study evaluating the efficacy and safety of its lead therapeutic candidate, efzofitimod (AT

  • GlobeNewswire

    aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    SAN DIEGO, May 13, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on its proprietary tRNA synthetase biology platform, today announced that the Compensation Committee of aTyr’s Board of Directors has granted four employees nonstatutory stock options to purchase an aggregate of 113,400 shares of its common stock, each with an exercise price of $3.48 per share, which is equal to the closing

Advertisement
Advertisement